Microbiota Therapeutics Could Become Strong Ally in IBD Treatment

Treatments that target the microbiome could help when combined with current drugs that alter the immune system, the study authors wrote."Our current drug therapies for IBD achieve remission in only a fraction of patients.

In IBD, maintenance dosing will likely be required to achieve durable remission, the authors noted. For exploratory studies in ulcerative colitis, enema dosing has been more widely applied and required multiple doses during an induction period of 8-12 weeks, leading to a higher cumulative dose compared with rCDIs.

FMT's efficacy in Crohn's disease has been explored less, but two phase 1 trials show promise, the authors noted. In one study, involving patients with mild to moderate Crohn's disease, clinical remission was achieved in 67% of patients at 8 weeks after FMT, with no significant difference between delivery method, either colonoscopy or gastroscopy. In the other study, involving patients with colonic or ileocolonic Crohn's disease, steroid-free remission was achieved in 87.

"In terms of the route of administration, the priority should be on oral formulations to facilitate trial logistics, increase patient adherence and acceptability, and accelerate drug development pipelines," they added."While this alternative — or perhaps complementary — approach to current immunotherapies may not be immediately applicable to IBD treatment, it is clearly a next step for treating those patients who failed to completely respond to immune-based therapies," R.

In addition, clinical trials need to define whether microbial modulation should be used as separate or adjunctive therapy, Sartor said.

IBD - Inflammatory Bowel Disease IBD Microbiome Microbiota Fecal Transplantation Stool Transplant Fecal Bacteriotherapy Fecal Microbiota Transplantation FMT Faecal Transplant Faecal Transplantation Faecal Bacteriotherapy Faecal Microbiota Transplantation C. Diff Infection Clostridium Difficile Infection Clostridium Difficile-Associated Disease

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Cranberry extracts could boost microbiota and counter cardiometabolic diseasesCranberry extracts appear to improve intestinal microbiota and help prevent chronic diseases such as diabetes and cardiovascular diseases. The study reported beneficial effects after only four days of use.
Source: ScienceDaily - 🏆 452. / 53 Read more »

Fungal resistance in plants associated with heritable differences in microbiota abundancesSunflowers aren't just beautiful symbols of summer—they are also economically significant, ranking as the fourth most important oilseed crop in the world, and new research suggests that some bacteria might help protect the crop from white-mold destruction.
Source: physorg_com - 🏆 388. / 55 Read more »

Modifying Gut Microbiota May Enhance DMARD Efficacy in RAInvestigators have found evidence suggesting that bad bugs in the belly may contribute to inflammation in the joints, and that modulating gut microbes could improve rheumatoid arthritis treatment.
Source: Medscape - 🏆 386. / 55 Read more »

A new method for enzymatic synthesis of potential RNA therapeuticsA team of researchers at IOCB Prague led by Prof. Michal Hocek has developed a novel method for preparing ribonucleic acid (RNA) containing modified bases.
Source: physorg_com - 🏆 388. / 55 Read more »

Earth Therapeutics’ Foot Peeling Spray Removes Dead Skin ‘Instantly’Now’s the time to get your feet ready for sandal season.
Source: StyleCaster - 🏆 104. / 63 Read more »

Verve Therapeutics Pauses Gene-Editing Trial Due to Side EffectsThe experimental biotech startup Verve Therapeutics has paused the first phase of a human gene-editing trial due to strange side effects in a patient. The trial aims to reduce heart-attack-causing cholesterol in patients with familial hypercholesterolemia. Verve's proposed solution is to genetically alter the cholesterol-managing PCSK9 gene using 'VERVE-101' serum. However, a patient enrolled in the trial passed away from a heart attack last year.
Source: futurism - 🏆 85. / 68 Read more »